IL1B and inflammatory bowel disease: Increased IL-1β expression and an aberrantly activated IL-1β signaling explicitly correlates with disease progression in a broad spectrum of local or systemic acute and chronic inflammatory diseases such as severe systemic inflammatory response syndrome, sepsis, inflammatory bowel disease and rheumatoid arthritis, and malignancies such as myeloma.